Company Description
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Laxminarayan Bhat |
Contact Details
Address: 10080 N. Wolfe Road, Suite SW3-200 Cupertino, California 95014 United States | |
| Phone | 408-501-8881 |
| Website | revivapharma.com |
Stock Details
| Ticker Symbol | RVPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001742927 |
| CUSIP Number | 76152G100 |
| ISIN Number | US76152G1004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laxminarayan Bhat Ph.D. | Founder, Chief Executive Officer, President and Director |
| Narayan Prabhu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 28, 2024 | ARS | Filing |
| Oct 28, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 17, 2024 | PRE 14A | Other preliminary proxy statements |
| Sep 17, 2024 | 8-K | Current Report |
| Aug 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |